Yufang Gong
Research Subjects
Yufang Gong has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Xiao Sun
Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China
5 shared publications Mengyao Mu
Department of Pharmacy
3 shared publications- Qing Fan
Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, PR China
3 shared publications Xinyu Zhang
Tumor Research and Therapy Center
3 shared publicationsChenyu Wang
Department of Pharmacy
2 shared publicationsGuiqi Ma
Department of Pharmacy
2 shared publications
Latest Publications
- 24 January 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (5) , 4241-4255
Heterogeneous Magnetic Resonance Nanoprobe for Assisting Liver Fibrosis Three-Dimensional Reconstruction and Cascaded Therapy
Liver fibrosis is a chronic, progressive liver disease that can lead to irreversible cirrhosis and hepatocellular carcinoma. However, the early and accurate diagnosis of liver fibrosis remains a dilemma in clinical research. In this study, a gadolinium-palladium nanocluster with decapeptide (L10) and glucose oxidase (GOx) grafting (GPPGL) was developed for accurate liver fibrosis staging and synergistic antifibrotic therapy. L10, with a strong affinity for Collagen I, can mediate this nanoplatform to target the liver fibrosis region, enabling it to achieve enhanced accumulation in the liver. Therefore, GPPGL, with magnetic resonance imaging (MRI) contrast enhancement capacity, can accurately grade liver fibrosis to different degrees. Then, three-dimensional reconstruction and histogram-based features of MRI images are further conducted to quantitatively and qualitatively analyze the degree of liver fibrosis. GOx, with strong glucose consumption, can enhance the catalase- and peroxidase-like activities of the nanoplatform in a cascade. Systemic delivery of GPPGL can synergistically inhibit the activation of hepatic stellate cells and reduce their collagen production by alleviating liver fibrosis hypoxia, inducing ferroptosis, and achieving starvation therapy. No significant side effects during both histological and hematological examinations were observed. Therefore, GPPGL has promising prospects for achieving accurate liver fibrosis staging and synergistic antifibrotic therapy.
- 24 January 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (5) , 4241-4255
Heterogeneous Magnetic Resonance Nanoprobe for Assisting Liver Fibrosis Three-Dimensional Reconstruction and Cascaded Therapy
Liver fibrosis is a chronic, progressive liver disease that can lead to irreversible cirrhosis and hepatocellular carcinoma. However, the early and accurate diagnosis of liver fibrosis remains a dilemma in clinical research. In this study, a gadolinium-palladium nanocluster with decapeptide (L10) and glucose oxidase (GOx) grafting (GPPGL) was developed for accurate liver fibrosis staging and synergistic antifibrotic therapy. L10, with a strong affinity for Collagen I, can mediate this nanoplatform to target the liver fibrosis region, enabling it to achieve enhanced accumulation in the liver. Therefore, GPPGL, with magnetic resonance imaging (MRI) contrast enhancement capacity, can accurately grade liver fibrosis to different degrees. Then, three-dimensional reconstruction and histogram-based features of MRI images are further conducted to quantitatively and qualitatively analyze the degree of liver fibrosis. GOx, with strong glucose consumption, can enhance the catalase- and peroxidase-like activities of the nanoplatform in a cascade. Systemic delivery of GPPGL can synergistically inhibit the activation of hepatic stellate cells and reduce their collagen production by alleviating liver fibrosis hypoxia, inducing ferroptosis, and achieving starvation therapy. No significant side effects during both histological and hematological examinations were observed. Therefore, GPPGL has promising prospects for achieving accurate liver fibrosis staging and synergistic antifibrotic therapy.
- 7 October 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (41) , 36158-36170
Engineered Magnetic Resonance Nanoprobes for Visualizing Tumor Programmed Cell Death Ligand 1 Level and Enhancing Synergistic Radio Immunotherapy
Visualizing tumor programmed cell death ligand 1 (PD-L1) expression and synchronously using this target for effective tumor therapy present great prospects for clinical application. In this study, a gadolinium-hybridized platinum nanoplatform with dimeric PD-L1-antagonistic affibody (ZPD-L1) (GPPZ) was constructed. Leveraging the specific binding between ZPD-L1 and the tumor surface, ZPD-L1 could endow this nanoplatform with efficient PD-L1 targeting, enabling the efficient magnetic resonance imaging (MRI) visualization of PD-L1 expression. GPPZ, through its catalase- and peroxidase-like activities, can catalyze the production of O2 and the production of •OH, respectively, sensitizing radiotherapy and enhancing immunogenic cell death. In addition, ZPD-L1 can also terminate T cells' immune suppression by effectively inhibiting interactions of PD-1/PD-L1 to further enhance tumor immunotherapy. Systemic delivery of GPPZ resulted in MRI contrast enhancement of tumors with high levels of PD-L1 expression. Importantly, no obvious side effects can be observed in both histological and hematology examination. Therefore, this nanoplatform demonstrated promise for enhanced MRI visualization of tumor PD-L1 level and synergistic radio immunotherapy.
- 7 October 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (41) , 36158-36170
Engineered Magnetic Resonance Nanoprobes for Visualizing Tumor Programmed Cell Death Ligand 1 Level and Enhancing Synergistic Radio Immunotherapy
Visualizing tumor programmed cell death ligand 1 (PD-L1) expression and synchronously using this target for effective tumor therapy present great prospects for clinical application. In this study, a gadolinium-hybridized platinum nanoplatform with dimeric PD-L1-antagonistic affibody (ZPD-L1) (GPPZ) was constructed. Leveraging the specific binding between ZPD-L1 and the tumor surface, ZPD-L1 could endow this nanoplatform with efficient PD-L1 targeting, enabling the efficient magnetic resonance imaging (MRI) visualization of PD-L1 expression. GPPZ, through its catalase- and peroxidase-like activities, can catalyze the production of O2 and the production of •OH, respectively, sensitizing radiotherapy and enhancing immunogenic cell death. In addition, ZPD-L1 can also terminate T cells' immune suppression by effectively inhibiting interactions of PD-1/PD-L1 to further enhance tumor immunotherapy. Systemic delivery of GPPZ resulted in MRI contrast enhancement of tumors with high levels of PD-L1 expression. Importantly, no obvious side effects can be observed in both histological and hematology examination. Therefore, this nanoplatform demonstrated promise for enhanced MRI visualization of tumor PD-L1 level and synergistic radio immunotherapy.
- 29 November 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 502
A multifunctional nanoplatform capable of dual action on tumor PD-L1 for enhanced cancer theranostics
- 29 November 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 502
A multifunctional nanoplatform capable of dual action on tumor PD-L1 for enhanced cancer theranostics
- 6 May 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 166, 604-614
CCR2-overexpressing biomimetic carrier-free nanoplatform for enhanced cascade ferroptosis tumor therapy
- 6 May 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 166, 604-614
CCR2-overexpressing biomimetic carrier-free nanoplatform for enhanced cascade ferroptosis tumor therapy